Immunohistochemical Localization of Survivin in Serous Tumors of the Ovary

Applied Immunohistochemistry and Molecular Morphology

Volumn 12, Issue 1, 2004, Pages 40-43

  Tringler, Barbara ^a,b   Lehner, Rainer ^a   Shroyer, A Laurie ^c   Shroyer, Kenneth R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Borderline tumor; Cyst adenocarcinoma; Cystadenoma; Serous; Survivin

Indexed keywords

PEROXIDASE; SURVIVIN;

ADENOMA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STAINING;

EID: 1542724872     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200403000-00008     Document Type: Article

References (18)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. Philadelphia: WB Saunders, 2000.
3. Frankel A, Rosen K, Filmus J, et al. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res. 2001;61:4837-4841.
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
5. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med. 1997;48:267-281.
6. LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247-3259.
7. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177-11182.
8. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
9. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097-6102.
10. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
11. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119-125.
12. Lehner R, Bobak J, Kim NW, et al. Localization of telomerase hTERT protein and survivin in placenta: relation to placental development and hydatidiform mole. Obstet Gynecol. 2001;97:965-970.
13. Lehner R, Lucia SM, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol. 2002;10:134-138.
14. Takai N, Miyazaki T, Nishida M, et al. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Intl J Mol Med. 2002;10:211-216.
15. Hattori M, Sakamoto H, Satoh K, et al. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett. 2001;169:155-164.
16. Mahotka C, Liebermann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Dell Death Differ. 2002;9:1334-1342.
17. Rodriguez JA, Span SW, Ferreira CG, et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res. 2002;275:44-53.
18. Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene. 2000;19:1346-1353.